Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Observational, Pilot Study Evaluating the Efficacy and Safety of Pertuzumab for the Neoadjuvant Treatment of HER2-Positive Breast Cancer Patients in Real Life Setting

Trial Profile

An Observational, Pilot Study Evaluating the Efficacy and Safety of Pertuzumab for the Neoadjuvant Treatment of HER2-Positive Breast Cancer Patients in Real Life Setting

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Jun 2018

At a glance

  • Drugs Pertuzumab (Primary) ; Antineoplastics; Docetaxel; Paclitaxel; Trastuzumab
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms PerTe
  • Most Recent Events

    • 12 Jun 2018 New trial record
    • 05 Jun 2018 Results (n=65) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top